3D Drug Eluting Balloons Applications in Healthcare

3D Drug Eluting Balloons Applications in Healthcare Market Outlook

The global 3D drug-eluting balloons market is projected to reach approximately USD 2.33 billion by 2035, growing at a CAGR of about 8.5% from 2025 to 2035. This growth is primarily driven by the increasing prevalence of cardiovascular diseases, rising awareness regarding advanced treatment options, and ongoing technological advancements in drug delivery systems. The growing geriatric population, coupled with lifestyle changes leading to higher disease incidence, is anticipated to further propel market demand. Additionally, investments in healthcare infrastructure and an increasing number of clinical trials related to drug-eluting technologies will create lucrative opportunities for market growth. The shift towards less invasive surgical procedures and the improved efficacy of drug-eluting balloons compared to traditional methods are also significant contributors to the market’s expansion.

Growth Factor of the Market

Several key factors are driving the growth of the 3D drug-eluting balloons market. Firstly, the increasing incidence of coronary artery disease among the aging population is a significant factor, as it leads to higher demand for effective treatment options such as drug-eluting balloons. Secondly, advancements in balloon technologies, including the incorporation of 3D printing, are enhancing the precision and effectiveness of drug delivery, making these devices more appealing to healthcare providers. Furthermore, the growing preference for minimally invasive surgical procedures is compelling healthcare professionals to adopt 3D drug-eluting balloons over traditional stents and surgical methods, which often involve longer recovery times and increased risk of complications. Additionally, favorable regulatory approvals for innovative products in various regions have also boosted market confidence, prompting more manufacturers to invest in research and development. Collectively, these factors are expected to significantly influence the market trajectory favorably.

Key Highlights of the Market

• Projected growth to USD 2.33 billion by 2035 with an 8.5% CAGR.
• Rising prevalence of cardiovascular diseases driving demand for advanced medical solutions.
• Innovations in product design and drug delivery systems enhancing treatment efficacy.
• Increasing preference for minimally invasive surgical alternatives among patients and providers.
• Favorable regulatory environment facilitating the launch of new products in the marketplace.

By Product Type

Coated Balloons:

Coated balloons are designed with a specific drug coating that releases therapeutic agents to the target area during the inflation of the balloon. This innovative product type is gaining traction due to its ability to deliver medications directly to the diseased tissue, maximizing efficacy while minimizing systemic exposure. The increasing prevalence of conditions like coronary artery disease and the demand for effective treatment modalities are propelling the adoption of coated balloons. As healthcare providers seek to improve patient outcomes and reduce complications associated with traditional methods, the use of coated balloons is expected to rise significantly. Additionally, advancements in coating technologies and drug formulations further enhance the capabilities of these balloons, appealing to both patients and healthcare practitioners. Overall, this segment is set to witness robust growth in the coming years, supported by ongoing research and clinical validation.

Non-Coated Balloons:

Non-coated balloons represent a significant segment of the 3D drug-eluting balloon market. While they may not deliver drugs directly, they serve as effective mechanisms for vessel dilation and can be used in conjunction with other therapeutic interventions. The demand for non-coated balloons is often driven by their lower cost compared to their coated counterparts, making them attractive options for healthcare facilities with budget constraints. Additionally, as medical professionals continue to seek out versatile tools for various vascular procedures, non-coated balloons are gaining popularity for use in applications beyond drug delivery, including in surgical and diagnostic procedures. The market for non-coated balloons is expected to exhibit steady growth due to their essential role in interventional cardiology and peripheral vascular treatments.

By Application

Coronary Artery Disease:

Coronary artery disease (CAD) is among the leading applications for 3D drug-eluting balloons, given the high prevalence of this condition globally. These balloons are utilized to restore blood flow by treating narrowed or blocked coronary arteries, significantly improving patient outcomes. The increasing incidence of CAD, driven by factors such as sedentary lifestyles, obesity, and diabetes, is propelling the demand for effective treatment options, including 3D drug-eluting balloons. Furthermore, advancements in balloon technologies that offer improved deliverability and efficacy are further enhancing their application in CAD. The ongoing emphasis on reducing the risks of restenosis and enhancing procedural success rates continues to bolster the use of these innovative devices in coronary interventions.

Peripheral Artery Disease:

Peripheral artery disease (PAD) is another critical application for 3D drug-eluting balloons. This condition, characterized by narrowed arteries reducing blood flow to the limbs, creates a substantial need for effective treatment modalities. Drug-eluting balloons play a vital role in treating PAD by delivering therapeutic agents directly to affected areas, reducing the likelihood of restenosis. The growing prevalence of PAD, particularly among older adults and those with risk factors such as smoking and diabetes, is driving the adoption of 3D drug-eluting balloons in this application. Moreover, clinical studies continue to demonstrate the benefits of these devices over traditional treatment options, establishing their significance in peripheral interventions and contributing to market growth.

Neurovascular Disease:

The increasing use of 3D drug-eluting balloons in neurovascular disease is notable, as they provide an innovative approach to treating conditions such as intracranial aneurysms and arteriovenous malformations. These balloons can be utilized in endovascular procedures to deliver medications directly to the target site, enhancing the efficacy of treatment while minimizing systemic exposure. The growing understanding of neurovascular diseases and their implications on overall health has resulted in a heightened focus on developing advanced therapeutic solutions. As a result, 3D drug-eluting balloons are becoming increasingly integrated into neurovascular interventions. The ongoing advancements in imaging technologies and endovascular techniques are expected to further propel the adoption of these devices in neurovascular applications.

Others:

In addition to coronary artery disease, peripheral artery disease, and neurovascular diseases, several other applications utilize 3D drug-eluting balloons. These include treatment for conditions such as renal artery stenosis and treatment for vascular grafts. The versatility of drug-eluting balloons allows them to be applied in various vascular procedures, addressing a broader range of medical needs. As healthcare providers explore innovative solutions for diverse patient populations, the application of 3D drug-eluting balloons in these alternative avenues is expected to expand. The availability of clinical data supporting the efficacy of these devices in different settings will further bolster their adoption, contributing to overall market growth.

By Distribution Channel

Hospitals:

Hospitals are the primary distribution channel for 3D drug-eluting balloons, accounting for a significant share of the market. Being centers of advanced medical care, hospitals utilize these innovative devices in various interventional procedures, targeting a range of diseases, primarily in cardiology and vascular surgeries. The presence of skilled healthcare professionals, state-of-the-art facilities, and comprehensive patient management protocols in hospitals make them ideal settings for deploying drug-eluting technologies. As hospitals continue to invest in advanced medical technologies and improve patient outcomes, the demand for 3D drug-eluting balloons is anticipated to grow steadily. Additionally, hospital partnerships with medical technology companies for research and training initiatives further strengthen this distribution channel's potential.

Specialty Clinics:

Specialty clinics are increasingly emerging as vital distribution channels for 3D drug-eluting balloons. These clinics focus on specific areas of healthcare, such as cardiology or vascular surgery, offering targeted treatments and interventions that utilize advanced medical technologies. As patients seek out specialized care for conditions like coronary artery disease or peripheral artery disease, the demand for effective treatment options such as drug-eluting balloons is rising. Specialty clinics often emphasize personalized care and may provide less invasive procedures, which align with the growing preference for such interventions among patients. The expansion of specialty clinics is expected to boost the market for 3D drug-eluting balloons, as these facilities adopt innovative solutions to address patient needs effectively.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) are gaining traction as a distribution channel for 3D drug-eluting balloons due to their ability to offer same-day discharge for patients undergoing less invasive procedures. These centers are designed for outpatient procedures, making them attractive options for patients and providers looking to reduce hospital stay durations and associated costs. The adoption of innovative technologies such as drug-eluting balloons aligns with the ASC model, as they enable effective treatment while minimizing procedural risks. Furthermore, government and insurance policies promoting outpatient care and the increasing focus on cost-effective healthcare solutions are expected to drive growth in ASCs' utilization of drug-eluting technologies. This emerging channel is likely to enhance the accessibility of 3D drug-eluting balloons to a broader patient population.

Others:

In addition to hospitals, specialty clinics, and ambulatory surgical centers, other distribution channels are emerging for 3D drug-eluting balloons. These include online platforms and medical device wholesalers that facilitate the procurement and distribution of medical technologies. The rise of e-commerce in the healthcare sector has made it easier for healthcare providers to access innovative solutions, including drug-eluting balloons, which can be integrated into their practice. Additionally, direct-to-consumer approaches are starting to take shape, where patients may seek out advanced treatment options independently. As the market evolves, other distribution channels will likely play a role in expanding the reach and accessibility of 3D drug-eluting balloons.

By Drug Type

Paclitaxel:

Paclitaxel is one of the most widely used drugs in 3D drug-eluting balloons, primarily due to its proven efficacy in preventing restenosis in various vascular applications. The incorporation of paclitaxel in drug-eluting balloons allows for targeted delivery directly to the site of injury, significantly improving treatment outcomes for conditions like coronary artery disease. Studies have shown that paclitaxel can effectively inhibit cell proliferation and promote vascular healing, making it a preferred choice for many manufacturers. The ongoing research into optimizing the formulation and release kinetics of paclitaxel in drug-eluting balloons is expected to further enhance its therapeutic potential. As a result, the paclitaxel segment is projected to maintain a strong presence in the market, driven by the growing demand for effective treatment alternatives.

Sirolimus:

Sirolimus is another crucial drug used in 3D drug-eluting balloons, known for its immunosuppressive and antiproliferative properties. The use of sirolimus in vascular interventions aims to reduce the risk of restenosis by inhibiting smooth muscle cell proliferation and promoting endothelial healing. The growing body of clinical evidence supporting the efficacy of sirolimus in the context of drug-eluting balloons is driving its adoption in various applications, particularly in coronary and peripheral artery disease. Moreover, the development of advanced formulations of sirolimus is expected to enhance its compatibility with balloon technology, offering improved drug delivery and patient outcomes. As a result, the sirolimus segment is poised for significant growth in the coming years.

Zotarolimus:

Zotarolimus is gaining recognition as an effective drug option in 3D drug-eluting balloons, particularly for its role in reducing the risk of restenosis. As an analog of sirolimus, zotarolimus offers similar properties in terms of inhibiting smooth muscle cell proliferation. Its unique mechanism of action and favorable safety profile make it a valuable addition to the drug-eluting balloon market. Clinical studies have demonstrated promising results with zotarolimus-coated balloons, adding to the growing interest among manufacturers and healthcare providers. The increasing focus on improving patient outcomes and reducing complications associated with traditional stenting is expected to drive the demand for zotarolimus in drug-eluting balloon applications. Consequently, this segment is anticipated to experience robust growth as more healthcare practitioners recognize the benefits of this drug.

Others:

Besides paclitaxel, sirolimus, and zotarolimus, there are several other drug types being utilized in 3D drug-eluting balloons. These include emerging agents that are being investigated for their effectiveness in preventing restenosis and enhancing vascular healing. As research continues to evolve, new formulations and combinations of drugs are likely to emerge in the market, providing healthcare providers with additional options for patient treatment. The exploration of novel drug candidates and innovative drug delivery systems will significantly expand the scope of 3D drug-eluting balloons. As a result, this segment will likely witness growth as manufacturers capitalize on the advancements in drug development and delivery technologies.

By Region

The North American region holds a significant share of the 3D drug-eluting balloons market, driven by a well-established healthcare infrastructure, high prevalence of cardiovascular diseases, and a strong focus on medical innovation. The increasing adoption of minimally invasive procedures and advanced medical devices further supports market growth. In 2025, North America is projected to account for approximately 40% of the global market share. Additionally, the region benefits from a favorable regulatory environment that encourages the development and commercialization of new medical technologies, contributing to its robust market position. The CAGR for this region is expected to exceed 9%, underscoring the strong demand for 3D drug-eluting balloons in North America.

Europe follows closely behind, also representing a substantial market for 3D drug-eluting balloons. The region is experiencing a rising incidence of coronary artery disease and peripheral artery disease, coupled with an increasing focus on improving patient outcomes through advanced treatment options. In 2025, Europe is estimated to hold around 30% of the global market share. The implementation of stringent regulatory frameworks ensures the safety and efficacy of medical devices, fostering a conducive environment for market growth. Additionally, ongoing clinical studies and trials are paving the way for the introduction of innovative products in the European market, further enhancing its potential. The region is expected to see a CAGR of approximately 7.5% during the forecast period.

Opportunities

The 3D drug-eluting balloons market presents numerous opportunities for growth, particularly through technological advancements and innovations in drug delivery systems. As research in the field of drug-eluting technologies continues to evolve, manufacturers have the chance to develop next-generation devices that offer improved efficacy, safety, and patient compliance. The integration of smart technologies, such as real-time monitoring systems and personalized drug delivery mechanisms, can significantly enhance the outcomes of interventions using drug-eluting balloons. Furthermore, collaborations between medical technology companies and healthcare providers can lead to the development of specialized solutions tailored to meet the unique needs of various patient demographics, thereby expanding the market's reach. The increasing focus on regenerative medicine and gene therapy may also result in novel applications for drug-eluting balloons, creating further opportunities for innovation.

Another opportunity lies in the rising prevalence of chronic diseases globally, which is expected to surge the demand for advanced treatment modalities. With increasing awareness regarding vascular health and the importance of early intervention, patients are seeking out effective and minimally invasive options to address their medical conditions. As healthcare systems continue to invest in advanced treatment technologies, the adoption of 3D drug-eluting balloons is likely to witness significant growth. Additionally, emerging markets in Asia Pacific and Latin America present untapped potential for market expansion. As healthcare infrastructure improves in these regions, the demand for innovative medical devices is expected to rise, providing manufacturers with opportunities to penetrate new markets and establish a strong presence.

Threats

One of the major threats to the 3D drug-eluting balloons market is the presence of stringent regulatory requirements that manufacturers must comply with before launching products. Navigating through the complex regulatory landscape can be time-consuming and costly, deterring smaller companies from entering the market. Additionally, the failure of any product to meet safety and efficacy standards can result in severe financial losses and damage to brand reputation. Moreover, the increasing competition from alternative treatment options, such as drug-coated stents and other advanced vascular interventions, poses a significant challenge to the growth of the drug-eluting balloon market. As healthcare professionals continue to evaluate the best options for patient care, the preference for alternative treatments can hinder the adoption of 3D drug-eluting balloons.

Another concerning factor is the rising cost of medical devices and healthcare services, which may limit patient access to advanced treatment options. As healthcare costs continue to escalate, patients may be deterred from pursuing innovative therapies like 3D drug-eluting balloons, opting instead for less expensive alternatives. Additionally, uncertainties in reimbursement policies for specific procedures involving drug-eluting balloons can further complicate market dynamics, as healthcare providers may be reluctant to invest in these technologies without assured compensation. The need for extensive clinical evidence to support the use of 3D drug-eluting balloons can also delay market growth. These threats necessitate strategic planning and proactive measures by manufacturers to navigate the complexities of the healthcare landscape while ensuring patient access to vital treatment options.

Competitor Outlook

• Medtronic
• Boston Scientific Corporation
• Abbott Laboratories
• Cordis Corporation
• Terumo Corporation
• B. Braun Melsungen AG
• AngioDynamics, Inc.
• Asahi Intecc Co., Ltd.
• Essen Medical
• Biotronik SE & Co. KG
• iVascular, S.L.
• Vascular Solutions, Inc.
• MicroPort Scientific Corporation
• Endologix, Inc.
• Lexicon Pharmaceuticals, Inc.

The competitive landscape of the 3D drug-eluting balloons market is marked by the presence of several key players striving to maintain their market position through continuous innovation and strategic initiatives. Major companies such as Medtronic, Boston Scientific, and Abbott Laboratories are at the forefront, leveraging their extensive research and development capabilities to introduce advanced products that offer improved patient outcomes. These companies not only invest in product development but also focus on building strong relationships with healthcare providers to better understand their needs and tailor solutions accordingly. Furthermore, collaborations and partnerships are common strategies employed by these companies to expand their market reach and enhance their product offerings.

Medtronic, a leading player in the medical device sector, has made significant strides in the 3D drug-eluting balloons market with its advanced technologies and comprehensive range of offerings. The company's focus on innovation and investment in clinical research has allowed it to maintain a competitive edge and establish itself as a trusted brand among healthcare professionals. Collaboration with healthcare providers and participation in clinical trials further bolster Medtronic's position, enabling the company to remain at the forefront of product development and therapeutic advancements.

Similarly, Boston Scientific Corporation is recognized for its extensive portfolio of 3D drug-eluting balloons and commitment to advancing vascular care solutions. The company emphasizes a patient-centric approach, continually seeking feedback from healthcare professionals to refine its products. Additionally, Boston Scientific actively engages in partnerships with hospitals and specialty clinics to create tailored solutions that fit the specific needs of diverse patient populations. Through innovation and collaboration, Boston Scientific aims to enhance its market presence and drive growth in the competitive 3D drug-eluting balloons landscape.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Medtronic
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Essen Medical
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Endologix, Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 iVascular, S.L.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Cordis Corporation
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Terumo Corporation
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Abbott Laboratories
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 AngioDynamics, Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 B. Braun Melsungen AG
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Biotronik SE & Co. KG
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Asahi Intecc Co., Ltd.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Vascular Solutions, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Boston Scientific Corporation
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Lexicon Pharmaceuticals, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 MicroPort Scientific Corporation
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 3D Drug Eluting Balloons Applications in Healthcare Market, By Drug Type
    • 6.1.1 Paclitaxel
    • 6.1.2 Sirolimus
    • 6.1.3 Zotarolimus
    • 6.1.4 Others
  • 6.2 3D Drug Eluting Balloons Applications in Healthcare Market, By Application
    • 6.2.1 Coronary Artery Disease
    • 6.2.2 Peripheral Artery Disease
    • 6.2.3 Neurovascular Disease
    • 6.2.4 Others
  • 6.3 3D Drug Eluting Balloons Applications in Healthcare Market, By Product Type
    • 6.3.1 Coated Balloons
    • 6.3.2 Non-Coated Balloons
  • 6.4 3D Drug Eluting Balloons Applications in Healthcare Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Specialty Clinics
    • 6.4.3 Ambulatory Surgical Centers
    • 6.4.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 3D Drug Eluting Balloons Applications in Healthcare Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global 3D Drug Eluting Balloons Applications in Healthcare market is categorized based on

By Product Type

• Coated Balloons
• Non-Coated Balloons

By Application

• Coronary Artery Disease
• Peripheral Artery Disease
• Neurovascular Disease
• Others

By Distribution Channel

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

By Drug Type

• Paclitaxel
• Sirolimus
• Zotarolimus
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Medtronic
• Boston Scientific Corporation
• Abbott Laboratories
• Cordis Corporation
• Terumo Corporation
• B. Braun Melsungen AG
• AngioDynamics, Inc.
• Asahi Intecc Co., Ltd.
• Essen Medical
• Biotronik SE & Co. KG
• iVascular, S.L.
• Vascular Solutions, Inc.
• MicroPort Scientific Corporation
• Endologix, Inc.
• Lexicon Pharmaceuticals, Inc.